ProCE Banner Activity

How I Used Pegylated Asparaginase to Treat a Young Adult With ALL

Clinical Thought
In this commentary, a leukemia expert describes a best-case scenario for the use of an intensive chemotherapy regimen containing asparaginase in a 21-year-old woman with newly diagnosed acute lymphoblastic leukemia.

Released: November 07, 2022

Expiration: November 06, 2023

No longer available for credit.

Share

Faculty

Daniel J. DeAngelo

Daniel J. DeAngelo, MD, PhD

Chief, Division of Leukemia
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Jazz Pharmaceuticals, Inc.

Faculty Disclosure

Primary Author

Daniel J. DeAngelo, MD, PhD

Chief, Division of Leukemia
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Daniel J. DeAngelo, MD, PhD: consultant: AbbVie, Agios, Amgen, Autolus, Blueprint, Forty-Seven, Gilead Sciences, GlycoMimetics, Incyte, Jazz, Kite, Novartis, Pfizer, Servier, Takeda; researcher: AbbVie, Blueprint, GlycoMimetics, Novartis; DSMB: Daiichi-Sanko, Fibrogen.